An international Ki67 reproducibility study.
暂无分享,去创建一个
John M S Bartlett | Mitch Dowsett | Lisa M McShane | Dongxia Gao | Frédérique Penault-Llorca | Daniel F Hayes | A. Gown | S. Leung | T. Nielsen | M. Dowsett | Erika Mehl | W. Symmans | L. McShane | G. Viale | J. Bartlett | F. Penault-Llorca | W. Symmans | D. Hayes | M. Polley | L. Zabaglo | M. Mastropasqua | D. Gao | J. Hugh | T. Piper | R. Enos | Samuel C Y Leung | Torsten O Nielsen | Rebecca A Enos | Allen M Gown | Judith C Hugh | Mauro G Mastropasqua | Tammy Piper | Giuseppe Viale | W Fraser Symmans | Mei-Yin C Polley | Lila A Zabaglo | D. Hayes | J. Bartlett | Erika Mehl
[1] N. Horton. Multilevel and Longitudinal Modeling Using Stata , 2006 .
[2] Arvydas Laurinavicius,et al. Digital Image Analysis in Pathology: Benefits and Obligation , 2011, Analytical cellular pathology.
[3] M. Dowsett,et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Jarrod D. Hadfield,et al. MCMC methods for multi-response generalized linear mixed models , 2010 .
[6] C Caldas,et al. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.
[7] Joseph C Cappelleri,et al. A modified large-sample approach to approximate interval estimation for a particular intraclass correlation coefficient. , 2003, Statistics in medicine.
[8] B. Ljung,et al. Invasive breast cancer. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] S. Kunte,et al. Statistical computing , 1999 .
[10] Laura H. Tang,et al. Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods , 2012, The American journal of surgical pathology.
[11] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[12] A. Beckett,et al. AKUFO AND IBARAPA. , 1965, Lancet.
[13] A. Giobbie-Hurder,et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[15] Mikael Lundin,et al. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer , 2011, BMC clinical pathology.
[16] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.
[17] Ingvar Andersson,et al. Invasive breast cancer. , 2011 .
[18] M. Dowsett,et al. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women , 2009, Breast Cancer Research and Treatment.
[19] Vilppu J. Tuominen,et al. Grading of Neuroendocrine Tumors With Ki-67 Requires High-quality Assessment Practices , 2012, The American journal of surgical pathology.
[20] T. Kirkegaard,et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? , 2006, Histopathology.
[21] Harald Frick,et al. How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists , 2012, PloS one.
[22] M. Dowsett,et al. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer , 2009, Breast Cancer Research and Treatment.
[23] M. Dowsett,et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Olson,et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Anais Malpica,et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer , 2012, Histopathology.
[26] J M Bland,et al. Statistical methods for assessing agreement between two methods of clinical measurement , 1986 .
[27] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[28] Andrzej T. Galecki,et al. Linear mixed-effects models using R , 2013 .
[29] Gao Hai-feng,et al. Proliferation marker Ki-67 in early breast cancer , 2009 .
[30] S. Teutsch,et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.
[31] V. Adsay. Ki67 Labeling Index in Neuroendocrine Tumors of the Gastrointestinal and Pancreatobiliary Tract: To Count or Not to Count Is Not the Question, But Rather How to Count , 2012, The American journal of surgical pathology.
[32] E Leonardi,et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies , 2011, Diagnostic pathology.
[33] I. Ellis,et al. The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.
[34] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.